DHR Stock Price Today (October 2026) — DHR Analysis & Key Metrics 2026-10-07
DHR (DHR) is trading at $218.49, up 1.34% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Software growth opportunities.
- According to consensus analyst estimates, the 1-year price target is N/A (Target pending).
- Volatility is moderate (27.30% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (5.50% YoY) alongside competitive pressures in the Software space.
DHR Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
DHR - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $177.11B
P/E Ratio
Forward P/E: 22.97
Revenue Growth
Year over Year
Analyst Target
Target analysis pending
Key Investor Questions About DHR
What investors need to know before buying
Based on current market data, DHR presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 53.82)
- Fundamentals say: Looking solid (debt and growth supportive)
DHR's growth trajectory depends on its ability to expand within the Software sector while managing margin pressures.
- Future growth will depend on performance in core Software operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for DHR investors include debt exposure and competitive dynamics in the Software industry.
- $27.86B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Software.
52-Week Trading Range
Over the past year, DHR stock traded between N/A and N/A. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 27.30% annualized volatility and β=0.65, the stock exhibits low sensitivity to market moves—making DHR suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Moderate ownership metrics suggest a balanced supply-demand dynamic.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Danaher (DHR) Stock Looks Reasonable On Label Free Detection Growth
Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...
Cardinal Health (NYSE:CAH) Vs Danaher Corporation (NYSE:DHR) – Here’s The One Jim Cramer Said Did Better
Healthcare services and products company Cardinal Health (NYSE:CAH)’s shares are up by more than 10% year-to-date but are down by more than 8% since early September. Cramer discussed the firm’s share price performance in his morning appearance on September 15th and wondered whether the weakness was due to a rotation into AI stocks rather than […]
Danaher (DHR) Could Be 8% Below Fair Value Following Its Dividend Reaffirmation
Danaher (DHR) has reaffirmed its shareholder payout, with the Board approving a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to holders of record on September 30. The reaffirmed dividend lands at a time when Danaher’s short-term momentum has picked up. The 90-day share price return is 17.78% and the 1-year total shareholder return is 10.73%, even though the 5-year total shareholder return is down 25.46%. Compare Danaher’s mix of dividend income and recent...
ELV or DHR: Which Is the Better Value Stock Right Now?
ELV vs. DHR: Which Stock Is the Better Value Option?
3 Reasons DHR is Risky and 1 Stock to Buy Instead
Danaher currently trades at $204.89 per share and has shown little upside over the past six months, posting a middling return of 5%. The stock also fell short of the S&P 500’s 13.1% gain during that period.
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says
Thermo Fisher Scientific (TMO) and Danaher (DHR) are likely to return to mid-single-digit organic re
ILMN Stock Keeps Climbing. Should You Climb On?
A gene sequencing leader is on a powerful run fueled by real business quality, forcing investors to decide if the engine has more power than the price tag already reflects.
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher (DHR) Seen Deftly Navigating AI Integration
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]
Explore More Analysis for DHR
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 21, 2026 (before the open)
Frequently Asked Questions
Common investor questions about DHR
DHR (DHR) is currently trading at $218.49. The RSI (14-day) is at 53.8, indicating neutral territory. Volatility is moderate at 27.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for DHR (DHR): The trailing P/E ratio is 36.17, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 22.97, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.41, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.72. Price-to-Sales is 5.69. Valuation should be compared to its industry industry peers for context, as different sectors trade at different multiples.
There is currently no consensus analyst price target available for DHR. The stock is currently trading at $218.49. Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
DHR (DHR) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for DHR (DHR) investors include: 1. Moderate volatility (27.3% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. its industry sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is DHR's (DHR) current debt and financial health profile: Total debt stands at $27.86B. The debt-to-equity ratio is 0.53x, which is moderate and generally manageable for most companies. The current ratio is 1.65, indicating strong short-term liquidity. The quick ratio is 1.15. The company holds $4.35B in cash and equivalents. Free cash flow is positive at $4.33B, providing a cushion for debt servicing and shareholder returns.